Mountainfield builds new companies around development-stage drug candidates with the potential to transform patient care.
We form our companies around in-licensed drug candidates, world-class leadership teams, and syndicated capital raises from top-tier life science institutional investors. We also develop the strategy and establish the operations for our companies based on our long track record in biopharmaceutical leadership and operational roles spanning from small start-up biotechnology companies to multi-national pharmaceutical companies.
Mountainfield is inspired by and named for our late colleague and mentor, Tachi Yamada, MD (Yamada translates from Japanese to English as Mountainfield). Tachi was a physician-scientist who made an extraordinary impact on human health across academic medicine, pharmaceutical R&D, global health, and biotechnology start-ups. Among his many roles, Tachi was Chairman of Medicine at the University of Michigan, head of R&D at GSK and Takeda, and President of Global Health at the Bill and Melinda Gates Foundation.